Skip to main content
. 2022 Oct 24;23(21):12815. doi: 10.3390/ijms232112815

Figure 4.

Figure 4

Overview of indirectly targeted therapies that exploit aberrant chromatin remodeling in cancer. Specific vulnerabilities in cancer cells caused by loss-of-function in a chromatin-remodeling situation might be targeted for cancer therapy. Available inhibitors for each target involved in the genetic defect’s vulnerabilities conferred by aberrant chromatin remodeling are listed.